{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:35:06Z","timestamp":1770960906686,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T00:00:00Z","timestamp":1268697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Immunosuppressive therapies have proven valuable in treating patients with myelodysplastic syndromes (MDS). We evaluated the combination of equine anti\u2010thymocyte globulin (ATGAM<jats:sup>\u00ae<\/jats:sup>) and the soluble tumour necrosis factor receptor, etanercept (Enbrel<jats:sup>\u00ae<\/jats:sup>), in a phase II trial. Twenty\u2010five patients with MDS [4\u2010refractory anaemia (RA), 2\u2010RA with ring sideroblasts, 15\u2010refractory cytopenia with multilineage dysplasia (RCMD), 3\u2010RCMD and ring sideroblasts, 1\u2010RA with excess blasts type 1] in International Prognostic Staging System risk groups low (<jats:italic>n<\/jats:italic>\u2003=\u200311) or intermediate\u20101 (<jats:italic>n<\/jats:italic>\u2003=\u200314) were enrolled. All patients were platelet or red cell transfusion\u2010dependent. Nineteen patients completed therapy with ATG at 40\u2003mg\/kg per day for four consecutive days, followed by etanercept, 25\u2003mg subcutaneous twice a week for 2\u2003weeks, every month for 4\u2003months. Thirteen patients had haematological improvement (HI)\u2010erythroid, 2 HI\u2010neutrophil, and 6 HI\u2010platelet. One patient with a co\u2010existing diagnosis of multiple sclerosis and rheumatoid arthritis had a complete remission. The overall response by intent to treat analysis among the 25 patients was 56% (95% confidence interval 35\u201356%). Four patients did not complete their first course of therapy and one patient did not survive to the 8\u2010week post\u2010treatment assessment. Among patients who completed treatment and survived to the 8\u2010week assessment, 70% had at least haematological responses lasting for at least 5 to more than 36\u2003months. Thus, combination therapy with ATG and etanercept was active and safe in patients with MDS.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08145.x","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T08:13:18Z","timestamp":1268727198000},"page":"706-710","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Anti\u2010thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study"],"prefix":"10.1111","volume":"149","author":[{"given":"Bart L.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Fosdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Storer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Petersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,5,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009089441"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402356"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.03.016"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00933.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04136.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400844"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0155"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404747"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03381.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4423249.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00920.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-3-200208060-00007"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00201-6"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.5.1570.h81702001570_1570_1574"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3325"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00095-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-153700"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9214"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403239"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2867"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403124"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08145.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:35:26Z","timestamp":1697394926000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,17]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08145.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08145.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,17]]},"assertion":[{"value":"2010-05-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}